Biopharmaceutical companies operate in an environment of rising chronic disease, aging populations and an increasing demand from emerging markets. From an investor's point of view, a company's capacity to focus in long term value creation through investing in improving the access to medicine in low- and middle-income countries is a key factor for positively contribute to the development of emerging markets.
Providing access to high quality medicines is one of the biopharmaceutical industry’s main priorities. These companies have the capability to bring modern medicine to everyone, playing a major role in providing life-saving products for the two billion people that still lack access to them. Due to their expertise in the sector, they are able to strengthen supply chains, support development of healthcare infrastructures, and ensure widespread distribution of their products.
In the recent years drug spending in emerging markets has grown at a faster pace than in North America, Europe and Japan. Therefore, it has become business critical to build a reputation as a positive contributor to the development of emerging markets. The underlying purposes are not only ensuring that their products reach as wide a base of people as possible, but also that they do so efficiently with an eye toward long term value creation for shareholders.
To analyze how the industry evolved in this matter, it is used the information gathered in the Access to Medicine Index (ATMI) reports published in November 2014 and November 2016. It provides a comprehensive overview of the top 20 research-based pharmaceutical companies’ efforts to make medicines, vaccines and diagnostics more accessible in low- and middle-income countries.
Overall, a larger amount of companies have implemented strategies for increasing access to medicine, many of them approaching it as a way of developing business in emerging markets. More than 100 products for high-burden diseases entered the pipeline since 2014, being R&D one of the areas where there is evidence that the industry responds to externally identified needs.
The proportion of collaborative research models for high-priority, low-incentive products increased in the last two years. R&D conducted in partnership includes access plans more often and earlier than in-house R&D, highlighting that collaborative models are an effective mechanism for engaging the biopharmaceutical sector in R&D oriented to the needs of populations in low- and middle-income countries.
Modest improvements were achieved in terms of product deployment. Voluntary licensing have been expanding the last two years, more compounds have been covered by voluntary license agreements, and for the first time moving beyond HIV/AIDS and extending them to hepatitis C. Even though steps are promising, large middle-income countries (MICs) are often excluded from licenses despite the fact that they are home to the majority of the world’s poor. Efforts for moving the product from the pipeline to the patient differ across companies, but a persistent trend of limited registration of new products in countries where they are particularly needed dominates the industry.
Most of the companies analyzed by the ATMI have now engaged in equitable pricing strategies, tailoring prices to different population segments. Although companies are considering affordability for more products than they did in 2014, the proportion of the industry portfolio covered by such pricing strategies remains static at one-third.
The biopharmaceutical industry is very diverse and this is reflected in the way companies approach access to medicine, which access challenges they choose to address and how, and which products they prioritize. Evidence shows the industry is continuing to step up its efforts to improve access to medicine in developing countries. It is analyzed below the performance of biopharmaceutical companies in four key industry-levels:
The content displayed on this website is exclusively directed at qualified investors, as defined in the swiss collective investment schemes act of 23 june 2006 ("cisa") and its implementing ordinance, or at “independent asset managers” which meet additional requirements as set out below. Qualified investors are in particular regulated financial intermediaries such as banks, securities dealers, fund management companies and asset managers of collective investment schemes and central banks, regulated insurance companies, public entities and retirement benefits institutions with professional treasury or companies with professional treasury.
The contents, however, are not intended for non-qualified investors. By clicking "I agree" below, you confirm and acknowledge that you act in your capacity as qualified investor pursuant to CISA or as an “independent asset manager” who meets the additional requirements set out hereafter. In the event that you are an "independent asset manager" who meets all the requirements set out in Art. 3 para. 2 let. c) CISA in conjunction with Art. 3 CISO, by clicking "I Agree" below you confirm that you will use the content of this website only for those of your clients which are qualified investors pursuant to CISA.
Representative in Switzerland of the foreign funds registered with the Swiss Financial Market Supervisory Authority ("FINMA") for distribution in or from Switzerland to non-qualified investors is Robeco Switzerland AG, Josefstrasse 218, 8005 Zürich, and the paying agent is UBS Switzerland AG, Bahnhofstrasse 45, 8001 Zürich. Please consult www.finma.ch for a list of FINMA registered funds.
Neither information nor any opinion expressed on the website constitutes a solicitation, an offer or a recommendation to buy, sell or dispose of any investment, to engage in any other transaction or to provide any investment advice or service. An investment in a Robeco/Robeco Switzerland product should only be made after reading the related legal documents such as management regulations, articles of association, prospectuses, key investor information documents and annual and semi-annual reports, which can be all be obtained free of charge at this website, at the registered seat of the representative in Switzerland, as well as at the Robeco/Robeco Switzerland offices in each country where Robeco has a presence. In respect of the funds distributed in Switzerland, the place of performance and jurisdiction is the registered office of the representative in Switzerland.
This website is not directed to any person in any jurisdiction where, by reason of that person's nationality, residence or otherwise, the publication or availability of this website is prohibited. Persons in respect of whom such prohibitions apply must not access this website.